In the study, the firm will enroll previously treated patients whose tumors are positive for FRα based on IHC testing.
Novartis licensed PTC's PTC518 Huntington's disease program and related molecules and will pay $1 billion upfront as well as other costs.
The trials are evaluating an individualized neoantigen vaccine with Keytruda as an adjuvant therapy for non-small cell lung cancer.
The firm plans to put the proceeds toward further developing its cell therapy in CD33- or FLT3-expressing AML and for other R&D activities.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback